Your browser doesn't support javascript.
loading
Efficacy of Intralesional Candida Antigen Versus Measles, Mumps, and Rubella Vaccine Versus Topical Podophyllin in Treatment of Resistant Genital Warts.
Zayan, Hisham; Hosny, Ahmed H; Mamdouh, Meriam M; Tawfik, Yasmin M.
Afiliación
  • Zayan H; Departments of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.
  • Hosny AH; Department of Andrology and Venereology, Faculty of Medicine, Helwan University, Helwan, Egypt.
  • Mamdouh MM; Health Insurance Unit, Assiut, Egypt.
  • Tawfik YM; Departments of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.
J Cutan Med Surg ; 28(3): 253-258, 2024.
Article en En | MEDLINE | ID: mdl-38497287
ABSTRACT

BACKGROUND:

No single treatment is ideal for genital warts with high rate of resistance using conventional modalities as topical podophyllin; however, several intralesional immunotherapies are being tested nowadays, with variable results. In this study, we compared the safety and efficacy of treating resistant and recurrent genital warts by 2 intralesional immunotherapies [Candida antigen and measles, mumps, and rubella (MMR) vaccine] and compared them with topical podophyllin. PATIENTS/

METHODS:

A total of 45 patients with resistant or recurrent genital warts were enrolled in this study. Size and number of warts were detected in each patient, patients were divided into 3 groups. Group A injected with intralesional Candida antigen. Group B with intralesional MMR vaccine. Group C were treated with topical 25% podophyllin. Patients received a session every 2 weeks for 3 treatment sessions.

RESULTS:

With regard to the reduction in size and number of all warts, the best response was obtained in Candida antigen group where 46.7% showed complete clearance and 40% showed partial response followed by MMR group and the last was the podophyllin group, with no significant difference between them. Complete clearance of mother warts was noticed in 86.7% of Candida group, 53.3% in MMR group, and last 40% in podophyllin group, with a significantly better response in the Candida group (P = .027).

CONCLUSION:

Both intralesional Candida antigen and MMR vaccine are simple, safe, and effective treatment options with comparable results and better response than topical podophyllin.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Podofilino / Condiloma Acuminado / Inyecciones Intralesiones / Vacuna contra el Sarampión-Parotiditis-Rubéola / Antígenos Fúngicos Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Cutan Med Surg Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Podofilino / Condiloma Acuminado / Inyecciones Intralesiones / Vacuna contra el Sarampión-Parotiditis-Rubéola / Antígenos Fúngicos Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Cutan Med Surg Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Estados Unidos